Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-00299804 in KRAS Wild Type Advanced NSCLC
NCT00553254Phase 2Completed
- Sponsor
- Pfizer
- Start
- Feb 2008
- Primary completion
- Aug 2010
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dacomitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Recommended Phase 2 Dose at 21 days and Progression-Free Survival at Month 4. Started Feb 2008; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00553254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00553254.